BioMarin Hypertension Candidate Fails Phase II Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says Phase III phenylketonuria candidate, which has same active ingredient, not impacted by results.
You may also be interested in...
BioMarin Licenses UCSF Technology To Address Cause of Cystic Fibrosis
UCSF researcher Alan Verkman will have an ongoing role in lead optimization and development, BioMarin’s CEO tells “The Pink Sheet” DAILY.
BioMarin Licenses UCSF Technology To Address Cause of Cystic Fibrosis
UCSF researcher Alan Verkman will have an ongoing role in lead optimization and development, BioMarin’s CEO tells “The Pink Sheet” DAILY.
BioMarin Submits Kuvan For Phenylketonuria
Firm is asking FDA for a priority review, which would potentially allow for a late 2007 launch of the orphan drug.